|
NCT05462613
|
Phase II |
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib
Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) |
Recruiting |
FRA |
0 |
|
NCT03203525
|
Phase I |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Doxorubicin + Temsirolimus
|
Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer |
Recruiting |
USA |
0 |
|
NCT06997497
|
Phase III |
Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin
|
A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) |
Recruiting |
USA | ROU | POL | NLD | ISR | GBR | FRA | FIN | ESP | DEU | BRA | AUS | ARG |
6 |
|
NCT03750786
|
Phase III |
Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT) |
Completed |
USA | SWE | GRC | FRA | ESP | DEU | CAN | AUT | AUS |
1 |
|
NCT01910610
|
Phase III |
Cetuximab
Irinotecan + Panitumumab
Panitumumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Capecitabine + Oxaliplatin
Cetuximab + Irinotecan
Cetuximab + Fluorouracil + Irinotecan + Leucovorin
|
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) |
Active, not recruiting |
ISR | IRL | FRA |
0 |
|
NCT03635021
|
Phase III |
Fluorouracil + Irinotecan + Leucovorin + Panitumumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab
|
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) |
Active, not recruiting |
ESP |
0 |
|
NCT01442935
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
|
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases |
Completed |
FRA |
0 |
|
NCT07150403
|
Phase II |
Fluorouracil + Fruquintinib + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Fluorouracil + Fruquintinib + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer |
Not yet recruiting |
FRA |
0 |
|
NCT05480306
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
DKN-01 + Fluorouracil + Irinotecan + Leucovorin
Fluorouracil + Irinotecan + Leucovorin
|
Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) |
Completed |
USA | DEU |
1 |
|
NCT06820463
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil + Leucovorin + Panitumumab + Telisotuzumab vedotin
Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Telisotuzumab vedotin
|
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) |
Recruiting |
USA | ISR | GRC | FRA | ESP | CZE | AUT | AUS |
3 |
|
NCT04660812
|
Phase Ib/II |
AB680 + Etrumadenant + Zimberelimab
Regorafenib
Bevacizumab + Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab
Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (ARC-9) |
Completed |
USA | ITA | GBR | FRA | ESP |
1 |
|
NCT03828227
|
Phase III |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin
Bevacizumab + Capecitabine
|
Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) |
Active, not recruiting |
FRA |
0 |
|
NCT04595266
|
Phase II |
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody
Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody
|
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) |
Active, not recruiting |
ESP |
0 |
|
NCT04607421
|
Phase III |
Bevacizumab + Capecitabine + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Cetuximab + Encorafenib
Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin
|
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer |
Active, not recruiting |
USA | SWE | SVK | POL | NZL | NOR | NLD | ITA | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG |
9 |
|
NCT01622543
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Pelareorep
|
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer |
Completed |
CAN |
0 |
|
NCT04952753
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793
Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin
|
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) |
Terminated |
USA | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUS |
5 |
|
NCT02162563
|
Phase III |
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Fluorouracil + Irinotecan + Leucovorin + Panitumumab
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) |
Completed |
NLD | BEL |
0 |
|
NCT05983367
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202
|
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer |
Active, not recruiting |
FRA | ESP | BEL |
0 |
|
NCT03186326
|
Phase II |
Aflibercept + Fluorouracil + Irinotecan + Leucovorin
Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab
Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Fluorouracil + Irinotecan + Leucovorin + Panitumumab
Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
Avelumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) |
Completed |
FRA |
0 |
|
NCT02141295
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
RO5520985
Bevacizumab + Fluorouracil + Leucovorin
Fluorouracil + Leucovorin + RO5520985
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
|
A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) |
Terminated |
USA | GBR | FRA | ESP | BEL | AUT | AUS |
0 |
|
NCT07221357
|
Phase II |
BNT327 + Fluorouracil + Leucovorin + Oxaliplatin
BNT327 + Fluorouracil + Irinotecan + Leucovorin
BNT327 + Capecitabine + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer |
Not yet recruiting |
USA | TUR | SWE | ROU | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG |
7 |
|
NCT05253651
|
Phase III |
Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib
Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) |
Recruiting |
USA | SVK | POL | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG |
6 |
|
NCT02997228
|
Phase III |
Atezolizumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study |
Active, not recruiting |
USA |
0 |
|
NCT04310176
|
Phase II |
Bevacizumab + Capecitabine + Oxaliplatin
Bevacizumab + Capecitabine
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil
Bevacizumab + Fluorouracil + Valproic acid
Bevacizumab + Capecitabine + Valproic acid
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid
Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid
|
Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) |
Unknown status |
ITA |
0 |
|
NCT01212822
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer |
Completed |
USA |
0 |
|
NCT03414983
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin
|
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) |
Completed |
USA | ESP | CAN |
2 |
|
NCT02339116
|
Phase III |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
|
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2) |
Unknown status |
ITA |
0 |
|
NCT01006369
|
Phase II |
Hydroxychloroquine
Bevacizumab + Capecitabine + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
Completed |
USA |
0 |
|
NCT03117972
|
Phase II |
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Capecitabine
|
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) |
Terminated |
FRA |
0 |
|
NCT02563002
|
Phase III |
Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil + Irinotecan + Leucovorin
Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
Pembrolizumab
|
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) |
Completed |
|
0 |
|
NCT01871571
|
Phase II |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer |
Unknown status |
USA |
0 |
|
NCT01792934
|
|
Capecitabine + Oxaliplatin
Bevacizumab + Capecitabine + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (ORCHESTRA) |
Active, not recruiting |
NLD | GBR |
0 |
|
NCT01765582
|
Phase II |
Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
Bevacizumab
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer |
Terminated |
USA |
0 |
|
NCT07228832
|
Phase III |
Fluorouracil + Ivonescimab + Leucovorin + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
|
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer ((HARMONi-GI3)) |
Recruiting |
USA |
0 |